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Neonatal jaundice: aetiology, diagnosis 
and treatment
Neonatal jaundice is one of the most common clinical signs in newborn infants. Jaundice present as yellow discolouration of the skin 
and sclera in infants, indicating a raised serum 
bilirubin level leading to accumulation of bilirubin 
in the tissues, including the skin and mucous 
membranes. Jaundice is thought to be visible at 
bilirubin levels of around 90 mmol/litre in babies 
with pale skin tones. The detection of jaundice is 
more difficult in babies with dark skin tones, but the 
sclerae are always white and inspection of the eyes 
is a crucial part of visual assessment of jaundice. 
Around 60% of term and 80% of preterm infants 
develop jaundice in the first week of life and 10% of 
breastfed infants remain jaundiced up to 1 month 
of age. Jaundice was the most common reason for 
admission from home to neonatal units in England 
for term infants (Battersby et al, 2017).
Most infants who become jaundiced develop 
jaundice in the first week of life, and in the majority 
of cases it is mild and harmless. Breast-fed infants are 
more prone to develop physiological jaundice in the 
first week of life. The key challenge is to differentiate 
the rare baby with significant jaundice which might 
lead to bilirubin encephalopathy and kernicterus 
from the majority of babies in whom jaundice will be 
harmless. It is also essential to identify infants with 
conjugated hyperbilirubinaemia who have biliary 
atresia as early as possible to improve outcome. The 
outcome for babies with biliary atresia whose surgery 
is performed at less that 6 weeks of age is much 
better than in those whose surgery is delayed by late 
diagnosis. 
The current national guideline in UK from the 
National Institute for Health and Care Excellence 
(NICE) (2016) recommends a review of all infants 
with risk factors for neonatal jaundice within the first 
48 hours of life and assessment of serum bilirubin 
level in any infant with clinical jaundice. The risk 
factors are outlined in Table 1. 
Bilirubin metabolism
In newborn infants, bilirubin is mostly produced 
from the breakdown of red blood cells. Haemoglobin, 
Abstract
A significant proportion of term and preterm infants 
develop neonatal jaundice. Jaundice in an otherwise 
healthy term infant is the most common reason for 
readmission to hospital. Jaundice is caused by an 
increase in serum bilirubin levels, largely as a result of 
breakdown of red blood cells. Bilirubin is conveyed in 
the blood as ‘unconjugated’ bilirubin, largely bound to 
albumin. The liver converts bilirubin into a conjugated 
form which is excreted in the bile. Very high levels of 
unconjugated bilirubin are neurotoxic. Phototherapy 
is a simple and effective way to reduce the bilirubin 
level. Most term babies have ‘physiological’ jaundice 
which responds to a short period of phototherapy, 
and requires no other treatment. A few babies have 
rapidly rising bilirubin levels which place them at risk 
of kernicterus. Current management of jaundice in 
the UK is guided by the NICE guideline. Any infant with 
high serum bilirubin or a rapidly rising bilirubin level 
needs to be treated urgently to avoid neurotoxicity. 
High levels of conjugated bilirubin in a term baby can 
indicate biliary atresia, and babies with persisting 
jaundice must have their level of conjugated bilirubin 
measured. Preterm infants on long-term parenteral 
nutrition may develop conjugated jaundice which 
generally improves with the introduction of enteral 
feed and weaning of intravenous nutrition.
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released from broken-down red blood cells, undergoes 
a two-stage catabolism within the reticuloendothelial 
system to produce bilirubin. This unconjugated (or 
indirect) bilirubin is transported in the circulation 
bound with serum albumin. Unconjugated bilirubin 
combines with glucuronic acid in the smooth 
endoplasmic reticulum inside the liver to produce 
water-soluble mono- or di-glucuronides of bilirubin, 
commonly referred as conjugated (or direct) bilirubin. 
Conjugated bilirubin is a component of bile and 
enters the gut via the biliary system. Although a 
proportion of conjugated bilirubin can be hydrolysed 
by beta-glucuronidase to unconjugated bilirubin in 
the small gut, from where it is reabsorbed (the 
enterohepatic circulation), the majority is excreted 
with the stool. Establishing gut motility and a normal 
pattern of stooling is an important component of 
reducing the bilirubin load from the enterohepatic 
circulation in the first few days, which is part of the 
reason why breastfeeding support is an essential 
component of the management of neonatal jaundice. 
An excellent new e-learning resource package 
regarding physiology of bilirubin metabolism under 
NHS Health Education England will be available 
for health-care professionals (http://barnacle.e-lfh.
org.uk/elex/repository/MaterialManagement.
aspx?_materialId=15591&rl=prj&_prjid=15146).
Normal pattern of neonatal jaundice
Most newborn infants develop jaundice in the first 
week of life. In term infants, the serum bilirubin level 
reaches a clinically detectable level by day 3 or 4. This 
gradually falls over the next few days before reaching 
the normal childhood serum bilirubin level by the end 
of the second week of life. This is generally referred 
to as physiological jaundice. Although prolonged 
unconjugated jaundice was previously attributed 
mainly to ‘breast milk jaundice’, it is becoming clear 
that many of these cases have an underlying genetic 
explanation (Bhutani, 2012). Up to one-third of 
exclusively breast-fed infants remain jaundiced at the 
end of 2 weeks and this group contributes to most 
community referrals to hospital for review at this age. 
A confident diagnosis of breast milk jaundice can 
only be made after exclusion of other possible causes 
and parents need an explanation of the nature of 
the problem. Beta-glucuronidase is present in breast 
milk and can cause increased levels of unconjugated 
bilirubin that enters the enterohepatic circulation 
from the gut. Altered gut flora in breast-fed infants 
has also been implicated in the reduction of the 
conversion of bilirubin glucuronides to urobilinoids. 
Jaundice in preterm infants is characterised by a 
higher peak in serum bilirubin levels along with a 
longer duration of hyperbilirubinaemia compared to 
term infants.  
Infants with bruising related to birth trauma, 
scalp haematoma (e.g. cephalhaematoma) and born 
after delayed cord clamping need to be carefully 
monitored early on as they have an increased risk of 
developing jaundice. 
Glucose-6-phosphatase deficiency (G6PD) is an 
important underlying cause of kernicterus, both 
worldwide and in the UK. Male babies of Asian 
ethnicity are particularly at risk but this condition is 
not confined to this group. 
Bilirubin encephalopathy
Sick and preterm infants are more vulnerable to the 
neurotoxic effect of raised bilirubin levels (Gartner 
et al, 1970). Pathophysiological mechanisms include 
cell membrane function disruption, lowering 
of action potential, disturbed energy metabolism 
and disturbance in neurotransmitter synthesis 
(Volpe, 2008; Brites et al, 2009). The deposition 
of bilirubin in the brain, noted during autopsy of 
infants who had died as a result of acute bilirubin 
toxicity, was described as ‘kernicterus’. Involvement 
of the brainstem, hippocampus, cerebellum, globus 
pallidus and subthalamic nuclei has been described. 
This anatomical predisposition might be related to 
increased metabolic activity and regional cerebral 
blood flow. 
Hypoxia, acidosis, hypercarbia, sepsis, seizures 
and disturbances to the blood–brain barrier are 
co-existing risk factors for acute bilirubin 
toxicity (Wennberg et al, 2006). Medications that 
interfere with bilirubin albumin binding or inhibit 
p-glycoprotein are implicated in increasing the risk of 
acute bilirubin encephalopathy (Watchko et al, 2002). 
More apoptosis was noted in less well-differentiated 
astrocytes and neurons (Brites et al, 2009) indicating 
Table 1. Factors related to higher susceptibility of 
newborn infants for development of physiological 
jaundice
High haemoglobin concentration in newborn infants
Immaturity of hepatic uptake, transport and conjugation 
system
Shorter lifespan for neonatal red blood cells compared 
to those of adults
Increased level of beta-glucuronidase in the gut, 
releasing more unconjugated bilirubin to enter the 
enterohepatic circulation
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the importance of the developmental stage of the 
brain in relation to bilirubin toxicity. A UK surveillance 
study has reported an occurrence of kernicterus in 1 
in 100 000 live births (Manning et al, 2007).
Risk factors for developing kernicterus are 
presented in Table 2. 
Previously described different stages of bilirubin 
encephalopathy (Connolly and Volpe, 1990) are now 
rare in current clinical practice. Opisthotonus (Figure 
1) generally indicates neuronal toxicity. Magnetic 
resonance imaging of the brain is the investigation 
of choice in suspected cases and presents a 
characteristic picture in cases of kernicterus (Figure 
2). High intensity areas in the posteromedial border 
of the globus pallidus on T2-weighted imaging is 
the most sensitive finding (Yokochi, 1995; Govaert 
et al, 2003). It is important to remember that long-
term neurological impairment can be associated 
with normal magnetic resonance imaging after acute 
bilirubin encephalopathy (Katar et al, 2008). Long-
term features include extrapyramidal disturbances, 
sensorineural hearing loss, auditory impairment and 
upward gaze palsies. The resultant cerebral palsy 
normally includes a degree of athetosis.
It is difficult to correlate a specific serum bilirubin 
level to the onset of bilirubin neurotoxicity. The 
report from the Pilot USA Kernicterus Registry 
suggested that a bilirubin level >598 mmol/litre can 
have a profoundly deleterious effect (Bhutani and 
Johnson, 2009).
Analysis of the NHS Resolution data regarding 
settled kernicterus claims in England also found that 
term babies had bilirubin levels above 600 mmol/
litre at presentation (J Rennie et al on behalf of the 
NHS Improvement Patient Safety Programme, 2017, 
unpublished data). 
Aetiology of neonatal jaundice
In view of the current era of early postnatal discharge 
and community support in the NHS, risk factors 
(Khoury et al, 1988; Newman et al, 2002; Keren 
et al, 2005; Maisels et al, 2009) associated with 
development of significant jaundice need to be 
reviewed before discharge (Table 3). The NICE 
(2016) guideline recommends that a second clinical 
examination is conducted before 48 hours of age.
A detailed family history and clinical examination 
is extremely important in all infants with jaundice for 
understanding of the possible aetiopathophysiology. 
Appropriate investigations can identify treatable 
conditions early (e.g. isoimmunisation, infection, 
biliary atresia) and improve outcome.
Early jaundice
Clinical jaundice within the first 24 hours of life is 
likely to be pathological and commonly a result of 
isoimmunisation (most commonly ABO or rhesus 
incompatibility) or other causes of significant 
haemolysis. Blood group and rhesus status for both 
mother and infant need to be reviewed along with a 
direct agglutination test (DAT). Anti-D prophylaxis in 
rhesus-negative mothers can cause a weakly positive 
DAT result as a result of passive transfer of antibody. 
A positive DAT test does not always correlate with 
the severity of jaundice (Bakkeheim et al, 2009). 
Reticulocyte count and blood film also carry a low 
Figure 1. Typical opisthotonic posture in a baby with neonatal 
jaundice and acute bilirubin encephalopathy.
Figure 2. Characteristic changes in kernicterus. a and b. 
Hyperintense signal and symmetrical scarring in globus pallidus 
on T2-weighted imaging on brain magnetic resonance imaging 
in kernicterus in two different cases and (c) macroscopic 
appearance of brain in kernicterus with characteristic yellow 
bilirubin staining.
Table 2. Risk factors associated with the development 
of kernicterus
Serum bilirubin level >340 mmol/litre in a term infant 
(≥37 weeks)
Rapid rise in the serum bilirubin level (>8.5 mmol/litre/
hour)
Clinical signs suggestive of bilirubin encephalopathy
a b c
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sensitivity and specificity for diagnosis of haemolysis 
in newborn infants (Newman and Easterling, 1994). 
Review of maternal antenatal notes often 
gives vital information about other blood group 
incompatibilities (e.g. Kell group) or the presence of 
other antibodies. Infection should always be excluded 
in sick newborns with early jaundice. Although G6PD 
deficiency-related jaundice presents after 48 hours, 
it needs to be part of the investigations in infants 
with relevant ethnicity (parents with Mediterranean, 
Asian or African origin). If haemolysis is ruled out, 
Crigler–Najjar syndrome should be considered. 
Although rare, it can develop a rapidly deteriorating 
non-haemolytic unconjugated jaundice early in life. 
Infants with G6PD deficiency can also present with 
non-haemolytic jaundice in the neonatal period.
Prolonged jaundice
Persistent clinical jaundice in term infants at 2 weeks 
and in preterm infants at 3 weeks of age is termed 
prolonged jaundice. This is a common referral from 
the community and mostly presents as unconjugated 
jaundice noted in breastfed infants. Feeding history, 
colour of stool and urine and clinical examination 
can mostly rule out pathological causes. The 
investigations should be done stepwise depending on 
the results from first-line investigations.
Initial investigations for infants with prolonged 
jaundice:
 l Check the colour of stool (whether yellow or pale 
chalky stool)
 l Check the urine (whether it is dark and stains the 
nappy easily)
 l Measure total and split bilirubin 
 l Full blood count, blood group and DAT
 l Liver function test
 l Urine culture and sensitivity
 l Ensure Guthrie card sent for routine metabolic 
screening
 l Thyroid function test
 l G6PD level. 
Conjugated jaundice
Serum conjugated bilirubin level of >25 mmol/litre 
is generally considered as conjugated jaundice. 
Although in clinical practice a 10% cut-off value 
for total serum bilirubin level is sometime used, 
this can give false reassurance in the case of high 
total bilirubin level. Pale chalky stool and dark 
urine can be important associated symptoms. Initial 
investigations should include a liver function test and 
check for any clotting abnormality. A liver ultrasound 
can provide further input in cases with suspected 
obstructive jaundice. Further investigations can rule 
out congenital infections, sepsis, glucosaemia and 
aminoacidaemias. Preterm infants on total parenteral 
nutrition often have a marked increase in conjugated 
bilirubin fraction which improves gradually after 
total parenteral nutrition is stopped.
Assessment of neonatal jaundice
Examination of the newborn for visual assessment 
of clinical jaundice should be performed in a well-lit 
room. Visual assessment is unreliable, particularly 
under artificial light and after phototherapy has 
begun. It can also be difficult in dark-skinned infants, 
in whom examination of sclera, gums and pinched 
skin are also important. For any infant with clinical 
jaundice, the serum bilirubin level must be measured 
to allow planning of management. Clinical jaundice 
usually becomes visually evident at a serum bilirubin 
level of 80–90 mmol/litre in babies with pale skin. 
In recent years, use of a transcutaneous 
bilirubinometer has transformed community care 
of jaundiced infants in UK. Bilirubin measurements 
from these instruments correlate well with serum 
bilirubin level and can avoid unnecessary blood tests 
and/or referral to hospital. Although transcutaneous 
bilirubinometer measurement highly correlates with 
serum bilirubin measurement, the average difference 
between these measurements was 12.7±32.9 mmol/
litre (Campbell et al, 2011), and this discrepancy 
increases further above levels of 250 mmol/litre. NICE 
guidance recommends checking a serum sample 
when transcutaneous bilirubinometer records 
indicates a bilirubin level higher than 250 mmol/litre. 
Most neonatal units in UK have the facility to 
estimate total serum bilirubin level from a bench 
bilirubinometer using direct spectrometry. For 
any specific measurement of conjugated and 
unconjugated bilirubin, a sample should be sent to 
the hospital biochemistry laboratory. 
The investigation pathway for neonatal jaundice 
(NICE, 2016) is presented in Figure 3.
Table 3. Risk factors in babies more likely to 
develop significant jaundice
Gestational age <38 weeks
History of previous sibling needing 
phototherapy
Exclusive breast feeding
Clinical jaundice visible within first 24 hours of 
life
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Management of neonatal jaundice
The management of neonatal jaundice is targeted 
at identifying the rare baby who has a rapidly rising 
bilirubin level and is at risk of kernicterus from the 
majority of term babies whose jaundice will remain 
harmless. Adequate early support (both pre-discharge 
and in the community) for mothers and infants for 
establishment of breast feeding reduces the risk of 
developing raised serum bilirubin level and can avoid 
the need for hospital readmission. 
Unconjugated jaundice
Phototherapy
Phototherapy is the first step in the management of 
raised unconjugated jaundice in newborn infants. It 
is a safe and convenient method of lowering serum 
bilirubin levels and reduces the need for more invasive 
treatment, exchange transfusion. Phototherapy 
is effective only after bilirubin enters the skin at 
serum bilirubin level >80 mmol/litre (Tan, 1982). The 
efficacy of phototherapy depends on the dose and 
wavelength of light used as well as the surface area 
of the infant’s body exposed to it. Increasing the 
dose can be achieved by placing phototherapy units 
at the minimum safe distance from the infant and 
increasing the number of units used. The American 
Academy of Pediatrics has defined the characteristics 
of a phototherapy device that contribute to the 
effectiveness in reducing the serum bilirubin level 
– emission of light in the blue–green range that 
overlaps the in vivo plasma bilirubin absorption 
spectrum (~460–490 nm) and a spectral irradiance of 
at least 30 microW/cm2/nm (Bhutani et al, 2011). 
Fibreoptic biliblankets are an effective way 
to reduce bilirubin level. They help to continue 
phototherapy during cuddles with parents and can be 
an effective way to give ‘double’ phototherapy when 
used together with an overhead unit. They can be 
placed in direct contact with the infant as they emit 
an insignificant degree of heat.
The predominant method of bilirubin elimination 
is the irreversible photoalteration of bilirubin to a 
structural isomer called lumirubin, which is a water-
soluble compound and is excreted with bile and 
urine. Two other important pathways of bilirubin 
photoalteration are photo-oxidation of bilirubin to 
colourless polar molecules that are excreted in the 
urine and configurational isomerization of bilirubin 
isomer to more water-soluble and less toxic isomers 
(Vreman et al, 2004).
Although phototherapy is generally benign, 
side effects can include diarrhoea, erythematous 
rash, increased fluid loss, temperature instability 
and skin discolouration (tanning and bronze baby 
syndrome). Improvement of phototherapy systems 
has dramatically reduced these side effects over the 
last decade.
The NICE (2016) guideline recommends the use of 
gestational age-specific treatment threshold graphs 
for babies with neonatal jaundice which is gestational 
age specific and gives a clear visual idea about the 
need for the modality of treatment at start as well as 
Figure 3. Investigation pathway for neonatal jaundice. Adapted from NICE (2016) guideline. 
AQ please confirm 
permission from 
NICE to reproduce 
this and figure 4 




information about neonatal 
jaundice (see page 9)
Ensure adequate support 
is offered to all women 
who intend to breastfeed 
exclusively³
Examine for jaundice at 
every opportunity, 
especially in first 
72 hours
The threshold table is on 
the foldout page at the 
front of this quick reference 
guide. The treatment 
threshold graphs are 




Identify babies as being more likely to develop significant 
hyperbilirubinaemia if they have any of the following factors:
•  gestational age under 38 weeks 
•  a previous sibling with neonatal jaundice requiring  
•  phototherapy mother’s intention to breastfeed exclusively 
•  visible jaundice in the first 24 hours
Does baby have any other factors?
•  gestational age under 38 weeks 
•  a previous sibling with neonatal jaundice requiring phototherapy  
•  mother’s intention to breastfeed exclusively
Does baby have suspected or obvious jaundice in the first 24 hours?
Routine care
Monitor bilirubin levels Treat using phototherapy Treat using exchange transfusion
Go to phototherapy pathway (see page 15) Go to exchange transfusion pathway (see page 16)
Measure and record serum bilirubin level within 6 hours
Does baby have visible jaundice?
Examine the baby for jaundice at every opportunity, especially in the first 72 hours
Manage hyperbilirubinaemia Interpret results using threshold table and treatment threshold graphs
Check for signs of acute 
bilirubin encephalopathy
Go to exchange transfusion 
pathway (see page 16)
Measure and record serum bilirubin level 
within 2 hours
Continue to measure the 
serum bilirubin level every 
6 hours until the level 
is both:
•   below the treatment 
threshold
•   stable and/or falling
Arrange a referral to 
ensure that an urgent 
medical review is 
conducted (as soon 
as possible and within 
6 hours) to exclude 
pathological causes of 
jaundice
Ensure babies 
receive an additional 
visual inspection 
by a healthcare 
professional within 
48 hours
Care for babies with 
signs of acute bilirubin 
encephalopathy
Urgent additional care for babies 
with jaundice in the first 24 hours
Additional care for 
babies who are more 
likely to develop 
hyperbilirubinaemia























the response to treatment. Two clear lines indicate the 
threshold of phototherapy and exchange transfusion 
over the first few weeks and days of life. Figure 4 
gives an example of the treatment threshold chart for 
infants ≥38 weeks gestation (NICE, 2016).
Pharmacological agents
High dose intravenous immunoglobulin is the 
only pharmacological treatment used in clinical 
practice for infants presenting with high jaundice 
levels secondary to rhesus or ABO isoimmunisation. 
Although it reduces the need for exchange transfusion, 
the duration of phototherapy and the length of 
hospital stay (Gottstein and Cooke, 2003), it is mostly 
used to buy time before starting exchange transfusion 
in severe cases of unconjugated jaundice.
Exchange transfusion
In recent years the need for exchange transfusion has 
significantly reduced because of improved antenatal 
management and the availability of improved highly 
effective phototherapy systems. It is an important 
intervention for infants who do not respond well to 
multiple phototherapy and appropriate hydration. 
It is also indicated in infants born with significant 
anaemia as a result of in utero haemolysis. In addition 
to the small risk of blood-borne infection, exchange 
transfusion carries a risk of morbidity and mortality 
from vascular injuries, cardiovascular complications, 
biochemical and haematological disturbance 
(Keenan et al, 1985). It is vital to monitor the infant 
closely throughout the procedure and check the 
haematological and biochemical parameters before, 
during and after exchange transfusion.
Conjugated jaundice
Identification of the aetiology is key for the 
management of an infant with conjugated jaundice. 
If a congenital obstruction is suspected, the infant 
needs to be reviewed in a surgical centre for further 
investigations and management. Biliary atresia is the 
most common surgically correctable liver condition in 
this age group and constitutes one fifth of the infants 
referred to one hepatobiliary referral centre in the UK. 
In one third of infants with biliary atresia stools are 
pigmented initially as the intra- and extrahepatic bile 
ducts may remain patent in the first few weeks of life. 
As they become atretic, the flow of bile stops and the 
colour of stool changes to a white, chalky appearance. 
Success of surgery is highest in earlier infancy, as 
with time, the intrahepatic biliary ducts obliterate 
and the chance of success of portoenterostomy drops 
significantly. Ursodeoxycholic acid (Willot et al, 
2008) and phenobarbital (Davenport et al, 1997) are 
used to improve the bile flow, and supplementation 
of fat-soluble vitamins is also required.
Prolonged use of parenteral nutrition causes 
cholestasis and hepatocellular damage in early 
infancy and the incidence increases with the degree 
of prematurity. Treatment focuses on increasing 
the bile flow with either ursodeoxycholic acid or 
phenobarbital and early introduction of enteral 
feeding.
Conclusions 
Neonatal jaundice is the most common condition 
needing medical attention in the neonatal period. The 
majority of these cases present with unconjugated 
hyperbilirubinaemia and most infants respond well 
to phototherapy when the bilirubin level reaches 
the treatment threshold. Infants with risk factors 
Key points
 l Neonatal jaundice is common in both term and 
preterm infants
 l In most cases the jaundice is harmless and requires 
no treatment or responds to phototherapy
 l High levels of unconjugated bilirubin can cause 
permanent brain damage, kernicterus 
 l High levels of conjugated bilirubin can be a marker 
of biliary atresia, which requires urgent surgery
 l The risk of kernicterus is low but means that all 
babies with jaundice should have their bilirubin 
levels monitored closely; babies with risk factors 
need an evaluation for jaundice at 48 hours. 
Treatment threshold graph for babies with neonatal jaundice
Baby's name        Date of birth
 
Hospital number     Time of birth         Direct Antiglobulin Test 	
Click below and choose gestation






































Figure 4. NICE treatment threshold graph for babies born at 
≥38 weeks. Individual charts need to be adjusted according to the 
gestational age before use.
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for developing significant hyperbilirubinaemia need 
to be monitored closely and treated early to prevent 
bilirubin neurotoxicity. Current research may, in 
future, facilitate the use of the camera facility on 
mobile phones as an objective measure of the colour 
of the sclerae (Leung et al, 2015). 
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